Anvisa – Informs the updates on the RDC 53/2015 and IN 258/2023 on qualified impurities is published
Anvisa (National Health Surveillance Agency) informs that RDC 821/2023 and IN 258/2023 was published on November 1, simplifying the qualification of impurities in pharmaceutical products. Listed impurities do not require a specific addition, while unlisted impurities require documentation for analysis. 

Read more here

If you need more information for drug regulatory issues, ELS can help with our registration services for your products.

Contact your local ELS consultant or via email

Contact us

We will contact you as soon as possible.